

POLICY NAME

Orilissa (elagolix)

POLICY #

2679P

Criteria

Exclusion Criteria – Any of the following prevents coverage

- ☐ **2.1** Orilissa will not be covered if the member is concurrently receiving therapy with a GnRH agonist or antagonist.
- ☐ **2.2** Continued coverage is not allowed after the originally approved regimen is completed (150mg daily for 24 months OR 200mg twice daily for 6 months)
 - Orilissa is associated with dose-dependent irreversible decrease in bone mineral density

Coverage Criteria

- ☐ **1.1** Diagnosis of moderate to severe pain associated with endometriosis
- ☐ **1.2** Age 18 years or older
- ☐ **1.3** Prescribed by or in consultation with an obstetrician-gynecologist (women's health doctor)
- ☐ **1.4** Documented failure, intolerance, or contraindication to a 3-month trial of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen AND oral contraceptives

Quantity Limit

- ☐ **3.1** 150mg: #30/30 days
- ☐ **3.2** 200mg: #60/30 days